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Introduction
Methotrexate (MTX), the disease modifying antirheumatic
drug (DMARD) of first choice in juvenile idiopathic arthri-
tis (JIA), is not effective in 45-50% of patients with polyar-
ticular course JIA. In developed countries, when MTX
fails, the next step is to start biologicals. In resource lim-
ited settings this step is constrained by prohibitive cost
and children failing MTX run the risk of poor disease con-
trol or steroid overuse. There is paucity of data on use of
other DMARDs or their combinations in such children.
MTX and leflunomide (LEF) are known to have differing
and complementary actions in modifying the immune
response and this combination has been studied in adults.
Their combined cost is a fraction of the cost of biologicals.
Objectives
To evaluate the benefits of addition of LEF in children
with polyarticular course JIA, non-responsive to standard
dose parenteral MTX.
Methods
In an observational study, 32 children with polyarticular
course JIA (JIA defined by modified ILAR criteria) fail-
ing standard dose MTX (up to 15 mg/m2/week sc for at
least 3 and up to 6 months) received additional LEF
(dosage by body weight). Permitted concomitant drugs
included pulse steroids for flares and/or low bridging
dose of prednisolone, intra-articular steroids and non-
steroidal anti-inflammatory drugs. No other DMARDs
were or had been used before enrolment. Patients were
assessed once every 8-12 weeks. Parameters recorded at
each visit included physician global assessment of disease
activity, parent/patient assessment of overall well-being,
functional ability, number of joints with active arthritis,
number of joints with limited range of motion and labora-
tory parameters, viz., hemogram, ESR and liver enzymes.
The primary efficacy outcome was the ACR Pedi 30 cri-
teria. At the end of follow up, Wallace’s criteria were used
to determine the percentage of children achieving
remission.
Results
25 of the 32 children who followed up for at least 3
months were analysed. The mean follow up duration was
1.61 years (range-0.29 to 3.0 years). At 3 months, 68% of
the patients met the ACR Pedi 30 response. 18 of the 21
children (85.7%) showed an ACR Pedi 30 response at
6 months. At 1 year, the percentage of ACR Pedi 30
response was 88.8% with good response rates seen using
the ACR Pedi 50 (83.3%), ACR Pedi 70 (61.1%) and ACR
Pedi 90 (50%) criteria. Of the 18 children who followed up
till the end of the study, 12 (66.6%) met the ACR Pedi 30
criteria and 9(50%) were in clinical remission on medica-
tions (off steroids). Adverse effects were observed in 2
children (gastritis and elevated liver enzymes in one each).
One child had macrophage activation syndrome tempo-
rally related to the introduction of LEF but it is difficult to
comment on a causal relationship. Only 2 children among
those failing the combination could afford biologicals, thus
highlighting the need for such studies. Of the 7 children
who were excluded from analysis,3 had developed hepati-
tis A and 4 had irregular visits.
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Conclusion
Our findings support the further study of the role of this
combination in the management of polyarticular course
JIA refractory to standard dose MTX, especially in resource
challenged settings. The open observational nature of the
study is its limitation.
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